Status:
RECRUITING
Efficacy and Safety of Dalbavancin As Suppressive Therapy
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Efficacy and Safety of Dalbavancin
In Subjects Who Received SAT with DAL
Eligibility:
All Genders
Brief Summary
Dalbavancin (DAL) is a semi-synthetic antibiotic that belongs to the lipoglycopeptide family and is structurally derived from teicoplanin, respect of which it has two structural differences that enhan...
Eligibility Criteria
Inclusion
- \> 18 years
- Patients received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024
- Patient who was informed and did not object to participating in the study
Exclusion
- -\< 18 years
- Subjects who received DAL not for SAT purposes
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06899906
Start Date
October 1 2024
End Date
May 1 2025
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HCL
France, Lyon, France, 69004